CHEPLAPHARM Arzneimittel GmbH
support_agent

Your contact persons

Press releases

01/05/2021

CHEPLAPHARM completes it´s largest acquisition so far

more chevron_right
Investors Domain

01/04/2021

CHEPLAPHARM acquires rights to Atacand® in more than 70 markets

more chevron_right
Press releases

01/04/2021

CHEPLAPHARM acquires rights to Atacand® in more than 70 markets

more chevron_right
Press releases

12/21/2020

CHEPLAPHARM donates over €200,000 for Christmas

more chevron_right
Investors Domain

12/16/2020

CHEPLAPHARM proves its vigour

more chevron_right
Press releases

12/16/2020

CHEPLAPHARM proves its vigour

more chevron_right
Investors Domain Investor Relations Archive

11/02/2020

CHEPLAPHARM closes another product portfolio acquisition

more chevron_right
Archive Investor Relations Investors Domain

11/02/2020

CHEPLAPHARM closes another product portfolio acquisition

more chevron_right
Investor Relations Archive

10/15/2020

CHEPLAPHARM succeeds again: 1 Billion Euros (equivalent) of Senior Secured Notes placed with institutional Investors

CHEPLAPHARM Arzneimittel GmbH has successfully gained a foothold in the US American institutional bond market.


more chevron_right
Investors Domain

10/15/2020

CHEPLAPHARM succeeds again: 1 Billion Euros (equivalent) of Senior Secured Notes placed with institutional Investors

CHEPLAPHARM Arzneimittel GmbH has successfully gained a foothold in the US American institutional bond market.


more chevron_right
Back to top expand_less